Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma by Wahn, Ulrich et al.
OR I G I N A L A R T I C L E
Airway Diseases
Real‐world benefits of allergen immunotherapy for birch
pollen‐associated allergic rhinitis and asthma
Ulrich Wahn1 | Claus Bachert2 | Joachim Heinrich3 | Hartmut Richter4 |
Stefan Zielen5
1Department of Paediatric Pneumology and
Immunology, Charité Medical University,
Berlin, Germany
2Upper Airways Research Laboratory,
Ghent University, Ghent, Belgium
3Institute of Epidemiology, Helmholtz
Zentrum Munich, German Research Centre
for Environmental Health GmbH,
Neuherberg, Germany
4IQVIA Commercial GmbH & Co. oHG,
Frankfurt am Main, Germany
5Division of Allergology, Pulmonology and
Cystic Fibrosis, Department of Paediatrics,
Goethe University Hospital, Frankfurt,
Germany
Correspondence
Ulrich Wahn, Im Hagen 26
D 14532 Kleinmachnow, Germany.
Email: Ulrich.wahn@gmail.com
Funding information
Stallergenes Greer
Abstract
Background: Real‐world evidence is sparse on the benefits of allergen immunother-
apy [AIT; subcutaneous/sublingual immunotherapy (SCIT/SLIT)], the only disease‐
modifying intervention for allergic rhinitis (AR) with long‐term efficacy. This real‐life
study evaluated the effect of six AITs (native pollen SLIT/SCIT, four allergoid SCITs)
vs symptomatic medication use, on AR symptoms and asthma symptoms/onset, in
patients with birch pollen‐associated AR and/or asthma.
Methods: In this retrospective cohort analysis of a German longitudinal prescription
database, AIT patients received ≥2 successive seasonal treatment cycles; non‐AIT
patients had ≥3 AR prescriptions in three seasons or previous month. Patients were
matched for: index year, age, gender, main indication at index, number of seasonal
cycles within treatment period, baseline AR/asthma treatment prescriptions. Multiple
regression analysis compared prescription data in AIT and non‐AIT groups as proxy
for clinical status/disease progression.
Results: Up to 6 years of follow‐up, significantly more AIT (65.4%) vs non‐AIT
(47.4%) patients were AR medication‐free; odds ratio (OR) [95% confidence interval
(CI)]: 0.51 [(0.48‐0.54); P < 0.001] (28.6% covariate‐adjusted reduction vs non‐AIT;
P < 0.001), and significantly more AIT (49.1%) vs non‐AIT (35.1%) patients were
asthma medication‐free [OR (95% CI): 0.59 (0.55‐0.65); P < 0.001] (32% reduction
vs non‐AIT; P < 0.001), or reduced existing asthma medication use (32% covariate‐
adjusted reduction vs non‐AIT; P < 0.001). During treatment, new‐onset asthma risk
was significantly reduced in the AIT vs non‐AIT group (OR: 0.83; P = 0.001).
Conclusions: Birch pollen AIT demonstrated real‐world benefits up to 6 years post‐
treatment cessation through significantly reduced AR and asthma medication intake,
and significantly decreased risk of new‐onset asthma medication use on‐treatment.
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1 | INTRODUCTION
Allergic rhinitis (AR) is a common inflammatory condition associated
with bothersome symptoms affecting the upper airways, nose and
eyes.1,2 AR affects up to 40% of the population worldwide, including
23%‐30% of people within Europe.3 Birch pollen is among the top
three most‐diagnosed allergens responsible for respiratory allergies,4
and birch is considered to be the major pollen‐allergen‐producing
tree in northern Europe,5 inducing mostly nasal symptoms.6 AR rep-
resents a considerable burden on public health, impacting daily activ-
ities, quality of life and productivity.1 It is also frequently associated
with various comorbidities, including asthma.1,7-10 AR often precedes
asthma,11-13 with the progression from AR to asthma considered
part of the “allergic march”,14 while uncontrolled AR may be associ-
ated with worsening of coexisting asthma.15
Allergen immunotherapy (AIT), in the form of subcutaneous or
sublingual immunotherapy (SCIT/SLIT), is the only treatment for AR
and/or allergic asthma (AA) with long‐term efficacy.16-19 In
randomized, double‐blind, placebo‐controlled studies, precoseasonal
administration of birch pollen SLIT for 2 years led to a significant
and sustained reduction in symptoms and symptomatic medication
use in patients with birch pollen‐associated allergic rhinoconjunctivi-
tis (ARC)5 and patients with AR plus asthma.20 However, long‐term
data from the real‐world setting, assessing the preventative role of
different AIT preparations on AR and/or AA progression, are
sparse.5,20-24 Real‐world studies are particularly valuable because
they can allow for longer observation periods and larger, more
heterogeneous patient cohorts than clinical trials.
There is ongoing debate on which, if any, is more effective in
AIT: native or modified allergen extracts, and SCIT or SLIT. It was
recently suggested that native preparations might be more effec-
tive25; on the other hand, modified preparations are usually associ-
ated with a lower side‐effect rate.26,27
Therefore, in the present analysis, we compared in a real‐life sit-
uation the effectiveness of 6 different birch or three‐tree (birch,
alder, hazel) pollen AITs (native SLIT/SCIT and 4 allergoid SCIT
preparations) vs a non‐AIT control group receiving symptomatic
treatment only, in patients with birch family pollen‐associated AR
and/or AA, to assess: (1) impact on AR progression, measured with
use of symptomatic AR medication ± AIT after active treatment ces-
sation; (2) impact on asthma occurrence in nonasthmatic patients,
during treatment and after active treatment cessation and (3) impact
on asthma progression in asthmatic patients, measured by the use of
symptomatic asthma medication ± AIT after active treatment
cessation.
This is the third analysis involving the LRx database and follows
two previous publications that demonstrated the long‐term, real‐
world benefits of grass pollen SLIT in patients with AR with or with-
out associated asthma in terms of slower AR progression, reduced
risk of new AA onset in AR patients with no associated asthma
comorbidity and slower AA progression in the AR population with
concomitant asthma.21,24
Retrospective cohort analysis of a German longitudinal prescription database
of patients with birch pollen-associated AR and/or asthma
*p<0.001 versus patients not using AIT
AIT, allergen immunotherapy (either native pollen SLIT drops, native pollen SCIT, or 4 allergoid SCITs);
AR, allergic rhinitis; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy
Patients never using AIT
47.4% 65.4%*
35.1% 49.1%*
Patients using AIT
At up to
6 years after
stopping treatment:
Patients not using
AR symptomatic
medication
Patients not using
asthma medication
GRAPHICAL ABSTRACT
In this retrospective, real-world study in Germany, birch pollen allergen immunotherapy (AIT) demonstrated significant benefits up to 6 years
post-treatment in patients with birch pollen-associated allergic rhinitis (AR) and/or asthma. AIT was associated with significantly improved AR
and asthma symptoms as the medication dispensing decreased; nearly two-thirds and one-half of patients initially using AR or asthma medica-
tions, respectively, no longer required them at study end. During the period in which they were receiving AIT, patients with AR but not asthma
had a significantly decreased risk of new-onset asthma medication dispensing.
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2 | METHODS
2.1 | Overall study design
This was a retrospective analysis of data extracted from a German
longitudinal prescription database (LRx, IQVIA, Frankfurt am Main,
Germany). The overall analysis period was June 2009 to February
2017.
Six birch family pollen AIT products available in Germany and
indicated for both AR and mild‐to‐moderate AA treatment were
analysed: natural SLIT drops, natural SCIT and four allergoid SCIT
preparations [two birch pollen extract formulations (Allergoid SCIT 1
and 2), a depigmented, polymerized birch pollen extract formulation
(Allergoid SCIT 3) and a formulation designed for ultra‐short‐course
administration (Allergoid SCIT 4)]. These products were chosen
based on the “List of AIT products in Germany” provided by the
German Society for Allergology and Clinical Immunology, in the
context of the current guideline on AIT in IgE‐mediated allergic dis-
eases,28 and were either “authorized allergen preparations with doc-
umented efficacy and safety, or preparations tradeable under the
German Therapy Allergen Ordinance, for which efficacy and safety
have already been documented in clinical trials meeting World
Allergy Organization”.29,30
2.2 | Datasets and proxy clinical data
The LRx database is updated monthly and contains information on
~60% of all prescriptions claimed by patients and reimbursed by
statutory health insurance funds in Germany. The dispensing date,
prescribing physician's Speciality, and full details of the medication
(brand, formulation, active compound, dose level, etc.) are provided
for each prescription. Patients’ age and gender are known in most
cases, and in line with German legislation on anonymized database
analysis, informed consent is not required. The LRx database does
not contain clinical information (eg, diagnoses); hence, patient pro-
files (eg, presence and/or progression of birch pollen AR and/or
asthma) must be inferred from proxy prescription data.
2.3 | Analytical time periods
For the AIT group, index date was defined as date of first prescrip-
tion of one of the selected AIT products. For the control group,
index date was defined as date of the second of three relevant
prescriptions in three consecutive three‐tree pollen seasons. This
had to be in the same index seasonal cycle as the index date of
the individual product patient matched to the corresponding con-
trol patient.
The pre‐index period was defined as the 365 days before index
date, and the treatment period was from index date of the first AIT
product to expiry date of the last prescription of this product. The
follow‐up period was from end of the treatment period to end of
study, and the full‐analysis period combined the treatment and fol-
low‐up periods.
2.4 | Patients and inclusion/exclusion criteria
Patients meeting the following criteria were included in the overall
AIT group: age ≥5 years; received treatment in ≥2 successive three‐
tree pollen seasonal cycles with one of the selected AIT products;
initiated treatment with one of these products between June 2009
and May 2013; had ≥1 defining prescription against AR (nasal corti-
costeroids, oral/systemic antihistamines) in the 365 days before
index date and/or ≥2 defining prescriptions against asthma [inhaled
corticosteroids (ICS), ICS/long‐acting beta agonists, short‐acting beta
agonists] in the three‐tree pollen seasonal cycle defined by index
season or the one immediately preceding it; and ≥2 years of follow‐
up (ie, observability) after treatment end.
Patients were excluded if they had received one of the selected
AIT products in the three‐tree pollen seasonal cycle before index
date; had received >1 of the selected products in their entire data-
base history (the only exception was switching between birch and
three‐tree pollen formulations inside one of the individual product
groups); had received any other AIT product in their entire database
history; had severe asthma (defined as having prescriptions of bio-
logics for asthma); or had perennial asthma [defined as ≥3 prescrip-
tions of ICS or methylxanthines, distributed over three successive 4‐
month periods (one such prescription each in January to April, May
to August and September to December) before or over the pollen
seasonal cycle of the index date] without exacerbations during the
season.
The control group included patients with AR and/or asthma
due to birch or three‐tree pollen who had not received any AIT
treatment in their entire database history. Patients in the control
group underwent exact matching with those in the AIT group
using the following criteria: index year, number of seasonal cycles
covered by the treatment period, age group at index date (5‐17,
18‐35, 36‐50 and >50 years), closest age match inside age group,
gender (male/female/unknown), main indication status at index date
(AR, asthma or both) and number of prescriptions of AR/asthma
treatment in the pre‐index period. To ensure that all medications
were actually prescribed for birch/three‐tree pollen allergy, it was
also required that at least the identifying prescriptions were dis-
pensed during the three‐tree pollen season (February to May) or
the month before it (January).
2.5 | Study endpoints
Study endpoints and primary analyses included: (1) AR progression
from 2 to 6 years after active treatment cessation in patients with
AR (± asthma) at baseline; (2) occurrence and time to development
of asthma in patients with AR without associated asthma at baseline,
during treatment and from 2 to 6 years post‐treatment; and (3)
asthma progression from 2 to 6 years after active treatment cessa-
tion in patients with asthma (± AR) at baseline. Secondary analyses
duplicated the primary analyses, but with the AIT group split into 6
individual AIT product subgroups, and the non‐AIT control group act-
ing as the reference for comparisons.
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2.6 | Statistical analysis
Descriptive statistics were presented for all outcome variables and
covariates, split by grouped or individual products (ie, overall AIT,
non‐AIT control, natural SLIT, natural SCIT and four individual aller-
goid SCIT formulations). Analyses of medication intake progression
(AR or asthma) were carried out by regression using a general linear
model, with the ratio of annual number of prescriptions in the analy-
sis period vs the pre‐index period used as the outcome variable.
Analysis of asthma medication intake as a Y/N variable was achieved
by logistic regression. Because the probability of asthma medication
intake occurrence would also depend on length of analytical time
span, the individual length of this period was included as a covariate.
Time to asthma medication intake was investigated using survival
analysis. The proportion of patients with any level of treatment
between the AIT and non‐AIT control groups was also analysed by
logistic regression. Statistical analyses were based on two‐way test-
ing without exception. For all statistical tests, significance level was
set to 5% (P < 0.05). Analyses were performed using SAS 9.4
software SAS Institute, Inc., Cary, NC, USA.
3 | RESULTS
In total, 9001 AIT patients and 45 005 matched non‐AIT control
patients were included, and their demographic and prescription‐
related characteristics at index are shown in Table 1. The majority of
patients (~85% for both AIT and non‐AIT groups) underwent ≤3 sea-
sonal cycles of treatment (Table 2), and only 14.8% of AIT patients
were treated for longer. The follow‐up period was slightly longer for
TABLE 1 Demographic and prescription‐related characteristics of patients in the AIT (overall and by product) and non‐AIT groups at index
date or during the pre‐index period
Parameter, n (%)
Non‐AIT
control
All
AIT Natural SLIT Natural SCIT
Allergoid
SCIT 1
Allergoid
SCIT 2
Allergoid
SCIT 3
Allergoid
SCIT 4
Patient disposition
Available for
matching
433 140 (100.0) 14 018 (100.0) 1282 (100.0) 1555 (100.0) 5714 (100.0) 2514 (100.0) 1464 (100.0) 1489 (100.0)
Successfully
matched
45 005 (10.4) 9001 (64.2) 838 (65.4) 1020 (65.6) 3728 (65.2) 1600 (63.6) 881 (60.2) 934 (62.7)
Using AR treatment
before index
31 745 (7.3) 6349 (45.3) 634 (49.5) 755 (48.6) 2603 (45.6) 1120 (44.6) 630 (43.0) 607 (40.8)
Using asthma
treatment before
index
10 900 (2.5) 2180 (15.6) 170 (13.3) 221 (14.2) 919 (16.1) 392 (15.6) 210 (14.3) 268 (18.0)
Using both AR and
asthma treatments
before index
2360 (0.5) 472 (3.4) 34 (2.7) 44 (2.8) 206 (3.6) 88 (3.5) 41 (2.8) 59 (4.0)
Age distribution at index, years
5‐17 8960 (19.9) 1792 (19.9) 193 (23.0) 199 (19.5) 667 (17.9) 320 (20.0) 253 (28.7) 160 (17.1)
18‐35 9700 (21.6) 1940 (21.6) 161 (19.2) 214 (21.0) 849 (22.8) 325 (20.3) 193 (21.9) 198 (21.2)
36‐50 15 410 (34.2) 3082 (34.2) 258 (30.8) 365 (35.8) 1298 (34.8) 564 (35.3) 267 (30.3) 330 (35.3)
>50 10 935 (24.3) 2187 (24.3) 226 (27.0) 242 (23.7) 914 (24.5) 391 (24.4) 168 (19.1) 246 (26.3)
Gender distribution at index
Male 13 640 (30.3) 2728 (30.3) 274 (32.7) 283 (27.7) 1137 (30.5) 477 (29.8) 263 (29.9) 294 (31.5)
Female 17 760 (39.5) 3552 (39.5) 320 (38.2) 389 (38.1) 1498 (40.2) 661 (41.3) 327 (37.1) 357 (38.2)
Unknown 13 605 (30.2) 2721 (30.2) 244 (29.1) 348 (34.1) 1093 (29.3) 462 (28.9) 291 (33.0) 283 (30.3)
Prescribing physician
ENT specialist 6232 (13.8) 2709 (30.1) 273 (32.6) 369 (36.2) 1200 (32.2) 401 (25.1) 237 (26.9) 229 (24.5)
Dermatologist 1945 (4.3) 2426 (27.0) 169 (20.2) 356 (34.9) 892 (23.9) 570 (35.6) 270 (30.6) 169 (18.1)
Pneumologist 1952 (4.3) 1335 (14.8) 70 (8.4) 53 (5.2) 730 (19.6) 233 (14.6) 92 (10.4) 157 (16.8)
Paediatrician 4461 (9.9) 936 (10.4) 62 (7.4) 85 (8.3) 307 (8.2) 178 (11.1) 185 (21.0) 119 (12.7)
Internal specialist 6534 (14.5) 417 (4.6) 36 (4.3) 47 (4.6) 183 (4.9) 60 (3.8) 26 (3.0) 65 (7.0)
General
practitioner
23 394 (52.0) 1109 (12.3) 208 (24.8) 99 (9.7) 399 (10.7) 151 (9.4) 66 (7.5) 186 (19.9)
Other speciality 487 (1.1) 69 (0.8) 20 (2.4) 11 (1.1) 17 (0.5) 7 (0.4) 5 (0.6) 9 (1.0)
AIT, allergen immunotherapy; AR, allergic rhinitis; ENT, ear, nose and throat; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy.
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the AIT vs non‐AIT group (Table 2), mainly due to differing treatment
patterns: symptomatic treatment is given during the pollen season,
whereas AIT should start before the pollen season commences.
3.1 | Progression of AR medication intake after
treatment cessation
At up to 6 years of follow‐up, significantly more patients in the AIT
group (n = 4459 of 6821 patients with AR at baseline; 65.4%) vs
non‐AIT group (n = 16 152 of 34 105 patients with AR at baseline;
47.4%) were treatment‐free [odds ratio (OR) [95% confidence inter-
val (CI)] for AIT: 0.51 (0.48‐0.54), P < 0.001] (Figure 1A), equating to
a 28.6% greater reduction in prescriptions in the AIT group after
covariate adjustment than the non‐AIT group (P < 0.001) (Fig-
ure 1B).
At follow‐up, a greater reduction from baseline was noted in
all AIT groups for average number of AR medication prescriptions
per patient per year [(baseline vs follow‐up values): overall AIT
and allergoid SCIT 1, both 1.72 vs 0.25; allergoid SCIT 2, 1.71 vs
0.23; allergoid SCIT 3, 1.68 vs 0.28; allergoid SCIT 4, 1.75 vs
0.31; natural SCIT, 1.72 vs 0.22; natural SLIT, 1.73 vs 0.23],
compared with the non‐AIT group (baseline: 1.73 vs follow‐up:
0.70).
3.2 | New asthma medication onset
Of 9001 AIT and 45 005 non‐AIT patients, 6349 (70.5%) and
31 683 (70.4%), respectively, did not have asthma at baseline. Of
these, 793 (12.5%) AIT and 4159 (13.1%) non‐AIT patients subse-
quently developed asthma (Figure 2).
During treatment, AIT patients had a significantly reduced risk of
new‐onset of asthma medication intake vs non‐AIT patients (OR:
0.83; P = 0.001) (Figure 3A). Up to 6 years after stopping treatment,
none of the products prevented the occurrence of new‐onset of
asthma medication intake in nonasthmatic patients. During the fol-
low‐up/post‐treatment period, the OR for the AIT group was close
to equality and therefore not significant (OR: 1.02, P = 0.77)
(Figure 3B). Over the 8‐year full‐analysis period, there was no signifi-
cant reduction in risk of new‐onset AA in the AIT vs non‐AIT group
(OR: 0.94; P = 0.16) (Figure 3C).
3.3 | Progression of asthma medication after
treatment cessation
At up to 6 years of follow‐up, significantly more patients in the AIT
group (n = 1302 of 2652 using asthma therapy at baseline; 49.1%)
vs non‐AIT group (n = 4654 of 13 260 using asthma therapy at
baseline; 35.1%) were asthma medication‐free [OR (95% CI) for AIT:
0.60 (0.55‐0.65); P < 0.001] (Figure 4A). In the follow‐up/post‐treat-
ment period, significantly less asthma medication was used in the
AIT vs non‐AIT group after covariate adjustment (32% reduction vs
non‐AIT; P < 0.001) (Figure 4B).
At follow‐up, a greater reduction from baseline was noted in all
AIT groups for average number of asthma medication prescriptions
per patient per year [(baseline vs follow‐up values): overall AIT (2.10
vs 0.61), allergoid SCIT 1 (2.07 vs 0.60), allergoid SCIT 2 (2.05 vs
0.65), allergoid SCIT 3 (2.14 vs 0.58), allergoid SCIT 4 (2.09 vs 0.72),
natural SCIT (2.14 vs 0.58), natural SLIT (2.23 vs 0.49)], compared
with the non‐AIT group (baseline: 2.11 vs follow‐up: 1.28).
4 | DISCUSSION
This retrospective, longitudinal analysis of the German LRx database
demonstrated that birch family pollen AIT was associated with signif-
icantly reduced AR progression, ie, less need for symptomatic medi-
cation. Nearly half of non‐AIT and two‐thirds of AIT patients were
no longer prescribed symptomatic AR treatment during the follow‐
up period. In the AIT group, this may be largely or even entirely due
to the effect of AIT to attenuate disease severity; in both groups,
particularly the non‐AIT group, this may be partly associated with
natural development of tolerance to the allergen. The level of base-
line AR treatment was higher in the non‐AIT group and was subse-
quently artificially reduced by matching to AIT patients. Therefore,
TABLE 2 Pattern of treatment administration in the patient groups receiving AIT
Parameter,
n (%)
Non‐AIT control
(N = 45 005)
All
AIT
(N = 9001)
Natural
SLIT
(N = 838)
Natural
SCIT
(N = 1020)
Allergoid
SCIT 1
(N = 3728)
Allergoid
SCIT 2
(N = 1600)
Allergoid
SCIT 3
(N = 881)
Allergoid
SCIT 4
(N = 934)
Seasonal cycles in treatment period
2 20 290 (45.1) 4058 (45.1) 328 (39.1) 399 (39.1) 1702 (45.7) 691 (43.2) 485 (55.1) 453 (48.5)
3 18 070 (40.2) 3614 (40.2) 307 (36.6) 418 (41.0) 1522 (40.8) 643 (40.2) 301 (34.2) 423 (45.3)
4 5985 (13.3) 1197 (13.3) 183 (21.8) 183 (17.9) 451 (12.1) 242 (15.1) 89 (10.1) 49 (5.2)
5 660 (1.5) 132 (1.5) 20 (2.4) 20 (2.0) 53 (1.4) 24 (1.5) 6 (0.7) 9 (1.0)
Average (SD) 2.71 (0.75) 2.71 (0.75) 2.88 (0.83) 2.83 (0.79) 2.69 (0.74) 2.75 (0.76) 2.56 (0.70) 2.59 (0.64)
Duration of follow‐up period, years
Average (SD) 4.16 (1.09) 4.41 (1.06) 4.35 (1.01) 4.61 (0.99) 4.52 (1.06) 4.38 (1.07) 3.97 (0.96) 4.31 (1.11)
Range 1.75‐6.08 2.00‐6.61 2.00‐6.48 2.01‐6.56 2.01‐6.61 2.01‐6.52 2.01‐5.56 2.00‐6.43
AIT, allergen immunotherapy; SCIT, subcutaneous immunotherapy; SD, standard deviation; SLIT, sublingual immunotherapy.
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OR: 0.51
P < 0.001
0.55
P < 0.001
0.49
P < 0.001
0.46
P < 0.001
0.60
P < 0.001
0.58
P < 0.001
0.31
P < 0.001 
n  = 34 105 6821 2809 1208 671 666 799 668
Control AIT 1 2 3 4 SCIT SLIT 
Allergoid SCIT Natural allergen
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the proportion of patients able to stop symptomatic AR treatment
may have been artificially increased in this group, meaning that the
comparative effectiveness of AIT on AR symptoms may be even
greater than that observed in the study.
This study also showed a significant reduction in the progression
of asthma medication use and a significantly decreased risk of new‐
onset asthma medication use during treatment with AIT. Analysis of
asthma medication occurrence showed that AIT might be associated
with a significantly reduced risk of developing asthma during treat-
ment, but a persistent post‐treatment effect could not be shown.
Statistical power to detect an effect on new‐onset asthma may have
been lowered, due to relatively few patients developing asthma and
(A)
Initiation of asthma medication
Odds ratio (95% CI), P value
0.83 (0.74-0.93), P = 0.001 
0.82 (0.70-0.96), P = 0.016 
All AIT
2.00.6 0.80.4 1.0
0.82 (0.65-1.03), P = 0.091 
1.05 (0.79-1.39), P = 0.759 
0.90 (0.67-1.22), P = 0.497 
0.81 (0.60-1.07), P = 0.139 
0.66 (0.47-0.91), P = 0.013 
More likely to
remain asthma-free
More likely to
develop asthma
6349
Allergoid SCIT 1 2603
Allergoid SCIT 2 1120
Allergoid SCIT 3 630
Allergoid SCIT 4 607
Natural SCIT 755
Natural SLIT 634
n
(B)
Initiation of asthma medication
Odds ratio (95% CI), P value
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F IGURE 3 Odds of starting asthma
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the low proportion of patients aged <18 years in the study (the abil-
ity of AIT to prevent asthma appears to be greatest in children29).
These findings are in contrast to those in a previous grass pollen
SLIT study,21 in which a sustained beneficial effect of SLIT on lower-
ing new‐onset asthma risk was noted in the post‐treatment period.
However, the grass pollen SLIT study included a much higher pro-
portion of children in the AIT group than did the present study
(~50% vs ~20%, respectively).
The present real‐world findings add to the current body of clini-
cal evidence demonstrating the benefits of AIT in patients with birch
pollen‐associated AR. In a randomized, double‐blind, placebo‐
controlled Phase IIIb study in patients with birch‐associated ARC
(N = 574), treatment for two consecutive pre‐ and coseasonal peri-
ods with birch pollen SLIT was associated with a sustained reduction
in symptoms and medication use, measured with the Average
Adjusted Symptom Score.5 In a randomized, double‐blind, placebo‐
controlled study of birch pollen SLIT administered using a precosea-
sonal protocol repeated for 2 years in patients presenting with sev-
ere rhinitis and slight to moderate asthma (N = 24), median number
of days with asthma at visit 3 was 10 vs 13 in the SLIT and placebo
groups, respectively, and at visit 6 was 2 vs 7, respectively (P < 0.05
between groups). A reduction in asthma medication intake occurred
in 77% of actively treated vs 0% of placebo‐treated patients
(P = 0.05).20
Allergoids are derived by chemical modification of allergens
using formaldehyde or glutaraldehyde (often followed by adsorption
to a carrier, such as aluminium hydroxide, tyrosine or monophos-
phoryl lipid A). This modification process induces conformational
changes in allergen proteins, so that they possess less‐reactive B‐
cell epitopes and thus reduced IgE binding, while their T‐cell epi-
topes and immunogenic effect remain unaltered. In comparison to
native allergens, a less‐pronounced allergic reaction occurs with
OR: 0.60
P < 0.001
0.59
P < 0.001
0.63
P < 0.001
0.49
P < 0.001
0.78
P = 0.029
0.55
P < 0.001
0.49
P < 0.001 
n  = 13 260 2652 1125 480 251 327 265 204
Control AIT 1 2 3 4 SCIT SLIT 
Allergoid SCIT Natural allergen
60
40
20
0
Pa
tie
nt
s 
no
t u
si
ng
 a
st
hm
a
m
ed
ic
at
io
n 
du
rin
g 
fo
llo
w
-u
p 
(%
)
35.1
49.1 49.7 47.7 50.2
41.9
53.2 53.9
(A)
n  = 2652 1125 480 251 327 265 204
AIT 1 2 3 4 SCIT SLIT 
Allergoid SCIT Natural allergen
0
–10
–20
–30
–40
–50
A
dd
iti
on
al
 re
du
ct
io
n 
in
 a
st
hm
a 
m
ed
ic
at
io
n
pr
es
cr
ip
tio
ns
 d
ur
in
g 
fo
llo
w
-u
p 
vs
 p
re
-in
de
x
pe
rio
d 
(c
om
pa
re
d 
to
 c
on
tr
ol
 g
ro
up
) (
%
 p
oi
nt
s)
–32.0 –33.7
–28.3
–26.1 –26.9
–37.3
–41.2
* *
* * *
*
*
(B)
F IGURE 4 Proportion of patients not
using asthma medication (A) and
percentage‐point reduction from baseline
in asthma medication use (B) during follow‐
up. *P < 0.001 vs non‐AIT control group.
AIT, allergen immunotherapy; OR, odds
ratio; SCIT, subcutaneous immunotherapy;
SLIT, sublingual immunotherapy
8 | WAHN ET AL.
allergoids because IgE‐binding sites are rendered inactive by their
altered chemical structure and fewer IgE antibodies can bind. Aller-
goids therefore exhibit lower allergenicity at the same level of
immunogenicity as native allergens19 and can be administered at
higher doses than native preparations. In the present study, the
effectiveness of the native SLIT or SCIT formulations was not infe-
rior to that of the allergoid formulations. Therefore, dosing regi-
mens and adherence may be additional considerations for the
patient and physician when choosing to use AIT. Over 3 years, SLIT
is administered daily pre‐ and coseasonally, conventional SCIT com-
prises >40 injections and ultra‐short‐course formulations require
just four injections; as shown in the present study, the latter are
effective but may have a more modest magnitude of improvement
compared with formulations that follow conventional or short‐
course administration.
Allergen immunotherapy also has significant benefits in reduc-
ing asthma risk in patients with grass pollen‐associated AR, ARC
and/or asthma. In the SQ grass SLIT tablet asthma prevention
(GAP) study in children aged 5‐12 years with grass pollen‐asso-
ciated AR (and no asthma) at enrolment (N = 812), 3 years of SLIT
treatment significantly reduced the risk of experiencing asthma
symptoms or using asthma medication after a 2‐year, untreated
follow‐up period and over the 5 years of the study (OR: 0.66;
P < 0.036). Moreover, both ARC symptoms and symptomatic med-
ication use were significantly reduced, by 22%‐30% (P < 0.005 for
all 5 years) and 27% vs placebo (P < 0.001), respectively.23 Simi-
larly, the Preventive Allergy Treatment (PAT) study showed that a
3‐year course of SCIT with standardized allergen extracts (birch
and grass pollen) in children resulted in long‐term clinical effects,
with a significantly lower asthma incidence among SCIT‐treated
patients (relative to symptomatic medication alone) observed at
7 years after treatment cessation.22,31 Finally, the prior analyses of
the LRx database provide real‐world evidence of the long‐term
benefits of grass pollen SLIT in patients with AR with or without
associated asthma in terms of slower progression of AR and AA
medication intake, and reduced risk of new‐onset asthma medica-
tion use.21,24
The current study used an improved patient‐matching process,
compared with the aforementioned grass pollen SLIT LRx database
analysis.21,24 Patients were stratified into AIT or non‐AIT groups and
matched by index year, age group, gender, main indication (AR/AA)
at index date, number of seasonal cycles while on treatment and
baseline AR/AA treatment prescriptions. This reduced confounding
and wide differences in covariate distribution helped align groups by
treatment‐period duration and avoided possible bias from intergroup
differences in baseline treatment levels. All AIT patients satisfying
inclusion/exclusion criteria were analysed and then matched 1:5 with
non‐AIT patients; therefore, the covariate distributions observed
reflect those of the overall AIT group, but may differ significantly
from those of the general non‐AIT patient population before
matching.
The high proportion of patients with unknown gender reflects
German practice in not recording gender information on
prescriptions. Instead, this was deduced/inferred from the first name
of the patient, and in cases of ambiguity, patients were recorded as
having “unknown” gender. Nevertheless, where known, the gender
distribution was consistently and notably skewed towards female in
the AIT group. It is unclear whether this reflects a genuine clinically
relevant, increased sensitivity of females to birch family pollen or
just an artefact of the selection process, because a study conducted
in children and adolescents in Germany reported a higher sensitiza-
tion to birch pollen among boys than girls.32
Differences in prescriber speciality between AIT and non‐AIT
groups reflect prescribing practice in Germany: AIT is mainly admin-
istered by ear, nose and throat (ENT) specialists and dermatologists,
while symptomatic treatment is typically prescribed by ENT special-
ists (if AR) or pneumologists (if asthma). Moreover, most of the anal-
ysed AIT products (excluding SLIT) must be administered by a
physician, unlike symptomatic medication, meaning that the general
practitioner plays a large role in treatment of the non‐AIT group,
compared with the AIT group.
This study had several limitations. No diagnoses are recorded in
the LRx database, meaning AR and asthma medication use had to
serve as a proxy to identify disease. Notably, there may have been
a risk of “false‐negatives” (ie, patients suffering from disease but not
identified) among patients with AR, because a large proportion of
AR medication (particularly antihistamines) is available over‐the‐
counter (OTC). This can affect both patient selection and subse-
quent assessment of AR progression. Nevertheless, any such bias
should have impacted both AIT and non‐AIT groups equally, mean-
ing that the relative between‐group comparisons and conclusions
remain valid. It was not possible to capture OTC medication use in
the study; however, in a survey of patients in France, Germany and
the UK with asthma and diagnosed AR (N = 936), 50% self‐reported
that they received AR medication prescriptions, while 21% used
OTC AR medications.33 The height of the birch pollen season in
Germany is April to early May, but it was assumed to extend further
into May for the present study; therefore, patients selected via med-
ication use in that month may have suffered from grass pollen‐
instead of birch pollen‐associated AR, particularly those in the non‐
AIT group who did not have confirmation of a prescription for birch
pollen‐specific AIT. While study inclusion/exclusion criteria were
designed to rule out polyallergy leading to AIT use against more
than one pollen type (or other allergens such as house dust mites),
this may not have been possible to completely achieve in practice.
Finally, it was not possible to check patient observability directly
because the LRx database only collects data on reimbursed prescrip-
tions; however, the necessity to have ≥1 AR and/or asthma prescrip-
tion(s) in the year before index acted partly as a proxy for checking
observability, and in fact eliminated around two‐thirds of patients
using AIT.
The main strengths of this study are that it was conducted in a
real‐world, large and inclusive patient cohort, with long‐term follow‐
up. It demonstrated high external validity (the study mirrors current
German clinical practice), and the stringent patient matching ensured
robustness of findings.
WAHN ET AL. | 9
5 | CONCLUSIONS
This real‐world study demonstrates the long‐term benefits of birch
family pollen AIT up to 6 years after treatment cessation via a signif-
icantly reduced progression of AR and asthma medication intake,
and a significantly decreased risk of new‐onset asthma medication
use during treatment.
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